Endocrine Abstracts

Aim: To investigate the glycaemic control of patients with T1DM before and after the introduction of CSII therapy.Methods: All patients with T1DM receiving CSII therapy for more than 6 months attending the Children’s University Hospital from 2005–2011 were included. Glycosylated haemoglobin (HbA1c) was recorded 12 and 6 months prior to starting therapy, at the time of CSII initiation and annually thereafter. Adverse events and BMI were also rec...